JP2016526574A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526574A5 JP2016526574A5 JP2016525817A JP2016525817A JP2016526574A5 JP 2016526574 A5 JP2016526574 A5 JP 2016526574A5 JP 2016525817 A JP2016525817 A JP 2016525817A JP 2016525817 A JP2016525817 A JP 2016525817A JP 2016526574 A5 JP2016526574 A5 JP 2016526574A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- alkyl
- nhs
- nhc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- -1 cyclooctynyl Chemical group 0.000 claims 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims 3
- 229930195729 fatty acid Natural products 0.000 claims 3
- 239000000194 fatty acid Substances 0.000 claims 3
- 150000004665 fatty acids Chemical class 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 108060008539 Transglutaminase Proteins 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 229960000956 coumarin Drugs 0.000 claims 1
- 235000001671 coumarin Nutrition 0.000 claims 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 102000035118 modified proteins Human genes 0.000 claims 1
- 108091005573 modified proteins Proteins 0.000 claims 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 102000003601 transglutaminase Human genes 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361845273P | 2013-07-11 | 2013-07-11 | |
| US61/845,273 | 2013-07-11 | ||
| US201462016044P | 2014-06-23 | 2014-06-23 | |
| US62/016,044 | 2014-06-23 | ||
| PCT/US2014/046409 WO2015006728A2 (en) | 2013-07-11 | 2014-07-11 | Site-specific chemoenzymatic protein modifications |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016526574A JP2016526574A (ja) | 2016-09-05 |
| JP2016526574A5 true JP2016526574A5 (enExample) | 2017-08-24 |
| JP6739333B2 JP6739333B2 (ja) | 2020-08-12 |
Family
ID=51298955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525817A Active JP6739333B2 (ja) | 2013-07-11 | 2014-07-11 | 部位特異的化学酵素的タンパク質修飾 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9359400B2 (enExample) |
| EP (2) | EP3613755A1 (enExample) |
| JP (1) | JP6739333B2 (enExample) |
| KR (1) | KR20160040556A (enExample) |
| CN (1) | CN105593238B (enExample) |
| AU (1) | AU2014286990A1 (enExample) |
| BR (1) | BR112016000585A2 (enExample) |
| CA (1) | CA2918076A1 (enExample) |
| EA (1) | EA201690205A1 (enExample) |
| ES (1) | ES2756526T3 (enExample) |
| MX (1) | MX2016000393A (enExample) |
| WO (1) | WO2015006728A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016000585A2 (pt) * | 2013-07-11 | 2018-03-20 | Novartis Ag | modificações quimioenzimáticas sítio-específicas de proteína |
| US10588980B2 (en) * | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| MX2018007451A (es) * | 2015-12-18 | 2018-11-09 | Eisai R&D Man Co Ltd | Inmunoglobulinas conjugadas con lisina c-terminal. |
| EP3436061A4 (en) | 2016-03-31 | 2019-12-04 | Liffey Biotech Limited | Saccharide-polypeptide-conjugate compositions and methods of use thereof |
| CA3026991A1 (en) | 2016-06-10 | 2017-12-14 | Eisai R&D Management Co., Ltd. | Lysine conjugated immunoglobulins |
| RS65362B1 (sr) | 2016-09-02 | 2024-04-30 | Sanofi Pasteur Inc | Vakcina protiv neisseria meningitidis |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| MX2019007910A (es) | 2016-12-30 | 2019-12-05 | Sutrovax Inc | Conjugados de polipeptido-antigeno con aminoacidos no naturales. |
| EP3691677A4 (en) | 2017-10-04 | 2021-07-07 | Pogona, Llc | COMPOSITIONS OF SACCHARIDE-POLYPEPTIDE CONJUGATES AND THEIR METHODS OF USE |
| MX2021008821A (es) * | 2019-01-25 | 2021-08-24 | Avedro Inc | Derivados de bis (diazirina) como foto-reticulante para el tratamiento de trastornos ectasicos de cornea. |
| EP4540263A2 (en) * | 2022-06-16 | 2025-04-23 | The General Hospital Corporation | Bicyclononyne reagents for cell imaging |
| CN119375471A (zh) * | 2023-07-26 | 2025-01-28 | 菲鹏生物股份有限公司 | 抗体和抗体缀合物及其用途 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPH0665280B2 (ja) | 1987-03-04 | 1994-08-24 | 味の素株式会社 | タンパクゲル化剤及びそれを用いるタンパクのゲル化方法 |
| DE4022267C2 (de) * | 1990-07-12 | 1994-09-15 | Degussa | N-Acyldipeptide und deren Verwendung |
| JP2849773B2 (ja) | 1990-08-27 | 1999-01-27 | 天野製薬株式会社 | ストレプトミセス属由来のトランスグルタミナーゼの製造法 |
| US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| US5425946A (en) | 1992-08-31 | 1995-06-20 | North American Vaccine, Inc. | Vaccines against group C Neisseria meningitidis |
| JP4097691B2 (ja) | 1992-08-31 | 2008-06-11 | バクスター、ヘルスケア、ソシエテ、アノニム | Ｃ群髄膜炎菌に対するワクチン |
| US5508191A (en) | 1993-07-05 | 1996-04-16 | Takeda Chemical Industries, Ltd. | Mutant strains of agrobacterium for producing β-1,3-glucan |
| DE69535037T2 (de) | 1994-08-26 | 2006-12-07 | Novozymes A/S | Mikrobielle transglutaminasen, ihre herstellung und ihre verwendung |
| EP0785276A4 (en) | 1994-09-29 | 2002-01-09 | Ajinomoto Kk | MODIFICATION OF A PEPTIDE AND A PROTEIN |
| EP0871712B1 (en) | 1995-01-19 | 2003-08-27 | Novozymes A/S | Transglutaminases from oomycetes |
| JP3669390B2 (ja) | 1995-02-09 | 2005-07-06 | 味の素株式会社 | バチルス属細菌由来のトランスグルタミナーゼ |
| US6284884B1 (en) | 1995-06-07 | 2001-09-04 | North American Vaccine, Inc. | Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof |
| EP0815833B1 (en) * | 1996-06-24 | 2003-04-09 | Givaudan SA | Malodour preventing agents |
| EP0950665A4 (en) | 1996-09-26 | 2004-05-06 | Ajinomoto Kk | PHYSIOLOGICALLY ACTIVE MODIFIED PROTEINS AND DRUG COMPOSITIONS CONTAINING THEM |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| US6919076B1 (en) | 1998-01-20 | 2005-07-19 | Pericor Science, Inc. | Conjugates of agents and transglutaminase substrate linking molecules |
| CA2318661A1 (en) | 1998-01-20 | 1999-07-22 | Howard Green | Transglutaminase linkage of agents to tissue |
| US6958148B1 (en) | 1998-01-20 | 2005-10-25 | Pericor Science, Inc. | Linkage of agents to body tissue using microparticles and transglutaminase |
| US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
| PT2332581E (pt) | 2001-01-23 | 2015-10-16 | Sanofi Pasteur Inc | Vacina meningocócica tri- ou tetravalente de conjugados de polissacárido e crm-197 |
| US7605175B2 (en) | 2001-03-02 | 2009-10-20 | Gpc Biotech Ag | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| JP2003199569A (ja) | 2001-12-17 | 2003-07-15 | Food Industry Research & Development Inst | ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ |
| DK1777236T3 (en) | 2002-03-26 | 2017-02-27 | Glaxosmithkline Biologicals Sa | MODIFIED SUCCARIDES WHICH IMPROVED WATER STABILITY FOR USE AS A MEDICINE |
| GB0211118D0 (en) | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| EP1787661A1 (en) | 2004-09-10 | 2007-05-23 | Toray Industries, Inc. | Medicinal preparation |
| CN101107010A (zh) | 2004-11-01 | 2008-01-16 | 布里格海姆妇女医院公司 | 经修饰的链球菌多糖及其用途 |
| GB0502096D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Purification of streptococcal capsular polysaccharide |
| EP1893239A2 (en) * | 2005-06-15 | 2008-03-05 | Novo Nordisk Health Care AG | Transglutaminase mediated conjugation of growth hormone |
| GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
| US8586532B2 (en) * | 2007-08-24 | 2013-11-19 | Novo Nordisk Healthcare A/G | Method for selectively modifying a protein via transglutaminase catalyzed reaction |
| WO2009032247A1 (en) * | 2007-08-30 | 2009-03-12 | Northwestern University | Synthetic peptide and peptide conjugates and related tissue coupling methods via transglutaminase enzyme |
| DE102007044296A1 (de) * | 2007-09-17 | 2009-03-19 | Hans-Lothar Prof. Dr. Fuchsbauer | Strukturmodulator von Proteinen |
| US8137925B2 (en) * | 2007-11-09 | 2012-03-20 | Massachusetts Institute Of Technology | Methods and compositions for protein labeling using lipoic acid ligases |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| WO2010002042A1 (ja) * | 2008-07-04 | 2010-01-07 | 国立大学法人 九州大学 | タンパク質ラベル化用酵素基質 |
| JP2012518029A (ja) * | 2009-02-19 | 2012-08-09 | ノヴォ・ノルディスク・アー／エス | 第ｖｉｉｉ因子の修飾 |
| FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
| WO2011002852A2 (en) | 2009-06-30 | 2011-01-06 | The Regents Of The University Of Michigan | Pro-drug complexes and related methods of use |
| US20110020837A1 (en) | 2009-07-07 | 2011-01-27 | Universiteit Utrecht Holding B.V. | Method for isolating or identifying a target protein interacting with a lipid in a cell |
| US8765920B2 (en) | 2009-12-23 | 2014-07-01 | The Scripps Research Institute | Tyrosine bioconjugation through aqueous Ene-like reactions |
| EP2894142B1 (en) * | 2010-04-27 | 2019-06-12 | SynAffix B.V. | Fused cyclooctyne compounds and their use in metal-free click reactions |
| EP2591354B1 (en) | 2010-07-07 | 2016-09-07 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| WO2012004419A2 (en) | 2010-07-09 | 2012-01-12 | Université De Bretagne Occidentale | Modular construction of lipophospholipids |
| WO2012058635A1 (en) | 2010-10-29 | 2012-05-03 | Life Technologies Corporation | Biotin derivatives |
| CA2930801C (en) | 2010-11-05 | 2019-05-28 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| AU2011338615B2 (en) | 2010-12-07 | 2017-07-27 | Yale University | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same |
| CA2814953A1 (en) | 2010-12-13 | 2012-06-21 | Immunomedics, Inc. | Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules |
| WO2012142659A1 (en) | 2011-04-19 | 2012-10-26 | Baker Idi Heart And Diabetes Institute Holdings Limited | Site-selective modification of proteins |
| FR2981352B1 (fr) * | 2011-10-17 | 2015-07-03 | Centre Nat Rech Scient | Procede de synthese de proteines |
| WO2013078564A2 (en) * | 2011-12-01 | 2013-06-06 | Angiochem Inc. | Targeted lysosomal enzyme compounds |
| JP5509440B2 (ja) * | 2012-06-22 | 2014-06-04 | 国立大学法人九州大学 | タンパク質−核酸複合体の製造方法および標的物の検出方法 |
| JP6744212B2 (ja) * | 2013-06-21 | 2020-08-19 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | ポリペプチドの酵素的結合 |
| BR112016000585A2 (pt) | 2013-07-11 | 2018-03-20 | Novartis Ag | modificações quimioenzimáticas sítio-específicas de proteína |
-
2014
- 2014-07-11 BR BR112016000585A patent/BR112016000585A2/pt not_active Application Discontinuation
- 2014-07-11 EP EP19187438.7A patent/EP3613755A1/en not_active Withdrawn
- 2014-07-11 EP EP14748350.7A patent/EP3019515B1/en active Active
- 2014-07-11 AU AU2014286990A patent/AU2014286990A1/en not_active Abandoned
- 2014-07-11 WO PCT/US2014/046409 patent/WO2015006728A2/en not_active Ceased
- 2014-07-11 CA CA2918076A patent/CA2918076A1/en not_active Abandoned
- 2014-07-11 KR KR1020167003053A patent/KR20160040556A/ko not_active Withdrawn
- 2014-07-11 MX MX2016000393A patent/MX2016000393A/es unknown
- 2014-07-11 US US14/329,758 patent/US9359400B2/en active Active
- 2014-07-11 ES ES14748350T patent/ES2756526T3/es active Active
- 2014-07-11 JP JP2016525817A patent/JP6739333B2/ja active Active
- 2014-07-11 CN CN201480046805.8A patent/CN105593238B/zh active Active
- 2014-07-11 EA EA201690205A patent/EA201690205A1/ru unknown
-
2016
- 2016-05-02 US US15/144,397 patent/US20160237116A1/en not_active Abandoned
-
2018
- 2018-11-29 US US16/204,557 patent/US10975120B2/en active Active
-
2021
- 2021-04-12 US US17/228,284 patent/US20220089639A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013510120A5 (enExample) | ||
| AR121016A2 (es) | Sales de fenotiazindiaminio y su uso | |
| EP4410317A3 (en) | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| JP2010527913A5 (enExample) | ||
| CY1118621T1 (el) | Πολυμορφικες μορφες του 2-(5-βρωμο-4-(4-κυκλο προπυλναφθαλιν-1-υλ)-4η-1,2,4-τριαζολ-3-υλθειο) οξικου οξεος και χρησεις αυτων | |
| JP2016520618A5 (enExample) | ||
| JP2021513534A5 (enExample) | ||
| JP2015061858A5 (enExample) | ||
| JP2017523225A5 (enExample) | ||
| JP2016505586A5 (enExample) | ||
| JP2012518029A5 (enExample) | ||
| ME02558B (me) | Inhibitori replikacije virusa gripa | |
| JP2012017342A5 (enExample) | ||
| JP2012513416A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| AR099134A1 (es) | Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina | |
| JP2016515561A5 (enExample) | ||
| JP2017531013A5 (enExample) | ||
| JP2024542188A5 (enExample) | ||
| JP2018531987A5 (enExample) | ||
| JP2015528463A5 (enExample) | ||
| AR070352A1 (es) | Derivado de pirrolopirimidina como inhibidor de la enzima pi3k, un procedimiento de elaboracion del compuesto, una composicion farmaceutica y un agente preventivo o terapeutico en base al compuesto. | |
| JP2015512946A5 (enExample) | ||
| JP2013514329A5 (enExample) | ||
| JP2016506386A5 (enExample) |